Jaktinib
Sponsors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd, First Affiliated Hospital of Zhejiang University
Conditions
Alopecia AreataAnkylosing SpondylitisAtopic DermatitisCOVID-19 PneumoniaHealthy ParticipantsModerate-to-Severe Plaque PsoriasisMyelodysplastic SyndromesMyelofibrosis
Phase 1
Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.
TerminatedNCT04866056
Start: 2021-09-30End: 2022-06-10Updated: 2022-12-01
A Study to Evaluate the Effect of Jaktinib on QT/QTc Interval in Healthy Participants
CompletedNCT06193148
Start: 2024-03-19End: 2024-06-18Updated: 2024-12-12
Phase 2
Clinical Study of Jaktinib in the Treatment of Patients With Moderate and Severe Atopic Dermatitis
CompletedNCT04539639
Start: 2020-12-02End: 2022-05-19Updated: 2023-03-24
A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis
CompletedNCT04612699
Start: 2021-03-11End: 2022-08-15Updated: 2025-02-20
Efficacy and Safety of Jaktinib in Patients With COVID-19 Pneumonia.
NCT05672888
Start: 2023-03-31End: 2024-05-31Target: 60Updated: 2023-01-17
Phase 3
Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis
CompletedNCT04617028
Start: 2021-02-05End: 2023-10-18Updated: 2023-11-13
Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata
CompletedNCT05051761
Start: 2021-09-04End: 2023-12-27Updated: 2025-03-14
Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata
CompletedNCT05255237
Start: 2022-03-25End: 2024-06-28Updated: 2025-03-18
Extension Study to Evaluate Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS)
RecruitingNCT05861128
Start: 2023-11-10End: 2025-12-31Target: 258Updated: 2024-01-11
Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS)
Active, not recruitingNCT05861102
Start: 2023-07-20End: 2026-07-31Updated: 2026-01-05